The Daily Papule

Meeting abstracts

SID 2026

Society for Investigative Dermatology · Chicago, 13–16 May 2026

1,214 abstracts, published in JID on 21 July 2026. Their text is on the JID website.

  1. 0014

    Disease signatures in responding vs. non-responding alopecia areata patients to baricitinib therapy

    Piccini I, Rouillé T, … senior author Edelkamp J

  2. 0111

    Envudeucitinib, an allosteric TYK2 inhibitor, inhibits TYK2-relevant biomarkers in skin using spatial transcriptomics

    Narayan N, Hoffman J, … senior author Tilley MK

  3. 0205

    Baseline anti-gliadin antibody positivity is associated with clinical efficacy of ritlecitinib in moderate-to-severe alopecia areata: A Chinese retrospective cohort

    Xu M, Wang Q, … senior author Wu W

  4. 0212

    A prospective study to evaluate the effectiveness of upadacitinib in moderate-to-severe AD with prurigo nodules in the real world in Japan: ADMIRE

    Murota H, Hagino T, … senior author Tada Y

  5. 0297

    Predicting clinical response to baricitinib in pediatric alopecia areata: Development of the baseline SALT-nail score

    Zhang X, Wang Q, … senior author Wu W

  6. 0300

    A prospective observational study of oral ivarmacitinib and narrow-band ultraviolet-B in refractory progressive vitiligo

    Chen J, Ou Y, Shao X

  7. 0330

    Merkel cell carcinoma arising in the setting of systemic janus kinase inhibitor therapy

    Bouché N, Park C, … senior author Nghiem P

  8. 0379

    Comparative effectiveness and safety of upadacitinib versus abrocitinib for moderate-to-severe atopic dermatitis: A retrospective real world study

    Hu Y, Zhang J, Zhao Y

  9. 0432

    Cutaneous graft-versus-host disease versus ruxolitinib-induced acneiform eruption in a hematopoietic stem cell transplant recipient: A diagnostic conundrum

    Mehta J, Block BR, … senior author Farabi B

  10. 0460

    Long-term laboratory trends in patients with moderate-to-severe atopic dermatitis treated with upadacitinib: 140-week results from measure up 1 and 2

    Cotter D, Shahriari M, … senior author Irvine A

  11. 0465

    Roflumilast foam 0.3% in patients with seborrheic dermatitis and prior inadequate response, intolerance, and/or contraindications to topical antifungals and/or topical corticosteroids

    Chovatiya R, Domingues E, … senior author Stephenson B

  12. 0476

    Evaluating the role of upadacitinib in refractory lichen planus: A systematic review

    Park JH, Gurram A, … senior author Linfante A

  13. 0488

    Rapid molecular and clinical improvement in cutaneous dermatomyositis with brepocitinib: Results from a phase 2 trial

    Mangold AR, Jiang R, … senior author Gudjonsson JE

  14. 0492

    Successful treatment of recalcitrant alopecia areata universalis with dual janus kinase inhibition using baricitinib and ritlecitinib

    Deol R, Bosch L, … senior author Quan V

  15. 0507

    A pilot study evaluating preliminary efficacy of deucravacitinib compared to placebo in the treatment of moderate-to-severe hidradenitis suppurativa (HS)

    Tehrani MD, Porter ML, … senior author Kimball AB

  16. 0513

    The use of topical roflumilast in the treatment of localized, steroid-refractory cutaneous immune-related adverse events: A single-institution real-life study

    Block BR, Mehta J, … senior author Gulati N

  17. 0525

    AI-driven discovery and mechanistic evaluation of cyclofuse: A novel small molecule for anti–hair-loss applications

    Lam K, Ng K, … senior author Chan C

  18. 0526

    AI-driven evaluation of polyceptin: A novel multi-target small molecule for anti–hair-loss applications

    Lam K, Ng K, … senior author Chan C

  19. 0527

    Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata

    Chen P, Hsieh T, … senior author Lin S

  20. 0530

    Once-daily roflumilast cream or foam 0.3% for psoriasis: Subgroup analysis by skin type (DERMIS-1/2 and ARRECTOR)

    Armstrong A, Lebwohl MG, … senior author Burnett P

  21. 0543

    Repigmentation outcomes with oral JAK inhibitors in vitiligo: A systematic review

    Gaumond SI, Abdshah A, … senior author Jimenez D

  22. 0546

    Cardiovascular and thromboembolic risk of janus kinase inhibitor use in dermatomyositis patients: A retrospective cohort analysis

    Park JH, Ramos-Briceño DA, … senior author Femia AN

  23. 0583

    Abrocitinib modulates itch-related gene expression in lesional and peri-lesional skin organ culture and skin biopsies from atopic dermatitis patients

    Zondler L, Fehrholz M, … senior author Watkins M

  24. 0606

    Contribution of STAT-3 gain-of-function mutation to cutaneous sclerosis ameliorated by JAK inhibitor therapy

    Buechler C, Pearson D

  25. 0941

    Reduction of skin CD8 TRMs in icotrokinra-treated participants with moderate-to-severe plaque psoriasis: Phase 3 ICONIC-LEAD results through week 52

    Angsana J, Ren Y, … senior author Bissonnette R

  26. 0969

    Molecular mechanisms of JAK inhibitor-induced acne: JAK inhibitors promote sebum production

    Sato T, Hayashi A, … senior author Koiwai T

  27. 1025

    AB102 is a potent and orally bioavailable small molecule inhibitor of MRGPRX2

    Serwas NK, Zhang L, … senior author Falahati R

  28. 1032

    Baricitinib blocks Th17 cytokines and independently stimulates filaggrin and loricrin expression in new ex vivo platform for IL-23-driven psoriasiform dermatitis

    Kenney S, Wu X, … senior author Hwang S

  29. 1062

    Evaluation of an injectable baricitinib hydrogel to treat alopecia areata and hidradenitis suppurativa

    Wang L, Kim E, … senior author Cotsarelis G

  30. 1063

    Serum olink proteomic analysis of the response to upadacitinib in alopecia totalis/universalis and correlation with efficacy

    Tao K, Wang Q, … senior author Lin J

  31. Late-breaking, LB1079

    Abrocitinib reduces tissue-resident memory T cells and restores epidermal barrier in atopic dermatitis: Results from JADE MOA trial

    Piccini I, Koudounas S, … senior author Bertolini M

  32. Late-breaking, LB1144

    The use of JAK inhibitors for immune-related adverse events: an institutional experience

    Osman A, Mittal L

  33. Late-breaking, LB1162

    Deucravacitinib response and single-cell keratinocyte programs in pityriasis rubra pilaris

    Penner SE, Roberts BT, … senior author Mangold AR

  34. Late-breaking, LB1221

    Profiling of severe refractory atopic dermatitis following failure of biologic and JAKi therapy

    Rault-Wang J, Schwartz R, … senior author Kibbie J

  35. Late-breaking, LB1225

    Baricitinib suppresses inflammation and restores epidermal barrier genes in a murine model of atopic dermatitis and psoriasis (AD-PsO) overlap

    Saito H, Wu X, … senior author Hwang S

That's every abstract.